New Data Available from Phase 3 Trial on Zeposia for Multiple Sclerosis
In early March 2024, Clinical Trials Arena reports that global biopharmaceutical company Bristol Myers Squibb shared new data from the Phase 3 DAYBREAK study. Within the study, researchers explored how…